Share

In This Section

Home / Resource Library Search

Resource Library Search Filter

Filter By Resource Library: Format Type
Filter By Resource Library: Topic

Resource Library Search

Letter to the Editor
Leukemia
"To identify complementary markers suitable for further treatment stratification in SR ALL, the study evaluated the predictive value of MRD and prospectively monitored MRD in 196 strictly defined SR ALL patients at up to 9 time points in the first year of treatment by quantitative polymerase chain reaction (PCR)."
Blood
"ALL is uniquely amenable to quantification of MRD by multiple techniques. Quantification of MRD with high-sensitivity methods not only facilitates risk stratification, but also is used to determine appropriateness of intensified therapy, such as allogeneic hematopoietic cell transplant, as well as MRD-targeted therapy with blinatumomab."
Clinical Advances in Hematology & Oncology
A database of privately and publicly funded clinical studies conducted worldwide.
U.S. National Library of Medicine
This analysis is based on a phase 2 study...investigating the combination of low-intensity chemotherapy (mini-hyper-CVD) in combination with INO with or without blinatumomab in patients with R-R ALL.
62nd ASH Annual Meeting and Exposition
"CatALLyst� is an initiative led by a multidisciplinary committee designed to encourage collaboration and provide the latest educational content."
Amgen
This workbook is written for the parent/guardian of a minor child (up to age 18), and includes information about caring for your child, treatment options, school, nutrition, financial and legal issues, and more.
The Leukemia and Lymphoma Society (LLS)
Preinfusion dim CD19 expression and rare CD19� events in B-ALL do not affect relapses or responses to CD19-directed CAR T-cells... Prior blinatumomab treatment increases the rate of failure to achieve MRD� remission and CD19� MRD and relapse.
Blood Advances
This handout provides an overview of cancer molecular profiling and its implications in the treatment of blood cancer.
The Leukemia and Lymphoma Society (LLS)
This booklet describes health insurance options and resources to help patients and their families who are coping with the financial aspects of cancer care.
The Leukemia and Lymphoma Society (LLS)
"Among adults with MRD-positive ALL in hematologic remission after chemotherapy, 78% achieved a complete MRD response with blinatumomab... Complete MRD response after blinatumomab treatment in this population was associated with significantly improved OS."
Blood
"Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following induction therapy in patients with ALL with relapse and mortality may improve the efficiency of clinical trials and accelerate drug development."
JAMA Oncology
ARUP offers MRD testing for ALL and other blood cancers.
ARUP Consult
The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data. The application of these guidelines ensures identical interpretation of MRD data between different laboratories of the same MRD-based clinical protocol.�
Leukemia
Learn about ALL through an interactive, web-based, illustrated story.
Medicine X
This booklet provides information for patients and their families about ALL in adults.
The Leukemia and Lymphoma Society (LLS)
This booklet provides information about ALL in children and also includes information about ALL in young adults.
The Leukemia and Lymphoma Society (LLS)
This website provides links to all of LLS's resources for patients with ALL.
The Leukemia and Lymphoma Society (LLS)
Authors developed and validated a prognostic index that assigns patient-specific risk scores and defines clinically relevant risk groups.
Blood
"A systematic literature review and meta-analysis were performed to elucidate the clinical significance of minimal residual disease with respect to relapse-free survival and overall survival in precursor B-cell ALL."
Haematologica